Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections – Drugs In Development, 2021, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 47, 23 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 16 and 13 molecules, respectively.
Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Zika Virus Infections - Overview
Zika Virus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Zika Virus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Zika Virus Infections - Companies Involved in Therapeutics Development
Zika Virus Infections - Drug Profiles
Zika Virus Infections - Dormant Projects
Zika Virus Infections - Discontinued Products
Zika Virus Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Zika Virus Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Zika Virus Infections - Pipeline by Activirosomes Ltd, 2021
Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, 2021
Zika Virus Infections - Pipeline by Akshaya Bio Inc, 2021
Zika Virus Infections - Pipeline by Altimmune Inc, 2021
Zika Virus Infections - Pipeline by Aravive Inc, 2021
Zika Virus Infections - Pipeline by Autonomous Therapeutics Inc, 2021
Zika Virus Infections - Pipeline by Bharat Biotech Ltd, 2021
Zika Virus Infections - Pipeline by Biken Co Ltd, 2021
Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, 2021
Zika Virus Infections - Pipeline by BioNet-Asia Co Ltd, 2021
Zika Virus Infections - Pipeline by Biotron Ltd, 2021
Zika Virus Infections - Pipeline by BravoVax Co Ltd, 2021
Zika Virus Infections - Pipeline by CanSino Biologics Inc, 2021
Zika Virus Infections - Pipeline by Cidara Therapeutics Inc, 2021
Zika Virus Infections - Pipeline by Ciloa, 2021
Zika Virus Infections - Pipeline by Cocrystal Pharma Inc, 2021
Zika Virus Infections - Pipeline by Codagenix Inc, 2021
Zika Virus Infections - Pipeline by CycloLab Cyclodextrin Research and Development Laboratory Ltd, 2021
Zika Virus Infections - Pipeline by Emergent BioSolutions Inc, 2021
Zika Virus Infections - Pipeline by Emergex Vaccines Holding Ltd, 2021
Zika Virus Infections - Pipeline by Enesi Pharma Ltd, 2021
Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, 2021
Zika Virus Infections - Pipeline by Enyo Pharma SA, 2021
Zika Virus Infections - Pipeline by Eurocine Vaccines AB, 2021
Zika Virus Infections - Pipeline by Excivion Ltd, 2021
Zika Virus Infections - Pipeline by Expres2ion Biotechnologies ApS, 2021
Zika Virus Infections - Pipeline by GeneOne Life Science Inc, 2021
Zika Virus Infections - Pipeline by GeoVax Labs Inc, 2021
Zika Virus Infections - Pipeline by Greffex Inc, 2021
Zika Virus Infections - Pipeline by Grifols SA, 2021
Zika Virus Infections - Pipeline by Hawaii Biotech Inc, 2021
Zika Virus Infections - Pipeline by Heat Biologics Inc, 2021
Zika Virus Infections - Pipeline by Hercules Pharmaceuticals BV, 2021
Zika Virus Infections - Pipeline by IDBiologics Inc, 2021
Zika Virus Infections - Pipeline by ImmunityBio Inc, 2021
Zika Virus Infections - Pipeline by Imutex Ltd, 2021
Zika Virus Infections - Pipeline by IMV Inc, 2021
Zika Virus Infections - Pipeline by Indian Immunologicals Ltd, 2021
Zika Virus Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
Zika Virus Infections - Pipeline by iosBio Pharma Ltd, 2021
Zika Virus Infections - Pipeline by Island Pharmaceuticals, 2021
Zika Virus Infections - Pipeline by Johnson & Johnson, 2021
Zika Virus Infections - Pipeline by Kamada Pharmaceuticals, 2021
Zika Virus Infections - Pipeline by KM Biologics Co Ltd, 2021
Zika Virus Infections - Pipeline by Macrophage Therapeutics Inc, 2021
Zika Virus Infections - Pipeline by Medigen Inc, 2021
Zika Virus Infections - Pipeline by Meletios Therapeutics SAS, 2021
Zika Virus Infections - Pipeline by Microbiotix Inc, 2021
Zika Virus Infections - Pipeline by Moderna Inc, 2021
Zika Virus Infections - Pipeline by Moleculin Biotech Inc, 2021
Zika Virus Infections - Pipeline by NanoViricides Inc, 2021
Zika Virus Infections - Pipeline by Novalex Therapeutics Inc, 2021
Zika Virus Infections - Pipeline by Orgenesis Inc, 2021
Zika Virus Infections - Pipeline by Ostrich Pharma USA Inc, 2021
Zika Virus Infections - Pipeline by Palisades Therapeutics, 2021
Zika Virus Infections - Pipeline by Pharos Biologicals LLC, 2021
Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, 2021
Zika Virus Infections - Pipeline by Precision Virologics Inc, 2021
Zika Virus Infections - Pipeline by ProtInhi BV, 2021
Zika Virus Infections - Pipeline by Replikins Ltd, 2021
Zika Virus Infections - Pipeline by Riboscience LLC, 2021
Zika Virus Infections - Pipeline by Sanofi, 2021
Zika Virus Infections - Pipeline by Sementis Ltd, 2021
Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, 2021
Zika Virus Infections - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Zika Virus Infections - Pipeline by TechnoVax Inc, 2021
Zika Virus Infections - Pipeline by TenGen Biomedical Co, 2021
Zika Virus Infections - Pipeline by Themis Bioscience GmbH, 2021
Zika Virus Infections - Pipeline by Theravectys SA, 2021
Zika Virus Infections - Pipeline by Tiba Biotech LLC, 2021
Zika Virus Infections - Pipeline by Touchlight Genetics Ltd, 2021
Zika Virus Infections - Pipeline by Tychan Pte Ltd, 2021
Zika Virus Infections - Pipeline by VBI Vaccines Inc, 2021
Zika Virus Infections - Pipeline by VenatoRx Pharmaceuticals Inc, 2021
Zika Virus Infections - Pipeline by Vir Biotechnology Inc, 2021
Zika Virus Infections - Pipeline by Virocovax, 2021
Zika Virus Infections - Pipeline by Xenothera SAS, 2021
Zika Virus Infections - Dormant Projects, 2021
Zika Virus Infections - Dormant Projects, 2021 (Contd..1)
Zika Virus Infections - Discontinued Products, 2021
List of Figures
Number of Products under Development for Zika Virus Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
